PI3K/AKT/mTOR Pathway and Pediatric T Acute Lymphoblastic Leukemia-Review.
10.7534/j.issn.1009-2137.2016.04.058
- Author:
Li-Xiao SHI
1
;
Jian-Hua WANG
2
;
Xiao-Dong SHI
3
Author Information
1. Department of Hematology, Capital Institute of Pediatrics, Beijing 100020, China.
2. Beijing Municipal Key Laboratory of Child Deve-lopment and Nutrions, Capital Institute of Pediatrics, Beijing 100020, China.
3. Department of Hematology, Capital Institute of Pediatrics, Beijing 100020, China.E-mail:xsusan28@gmail.com.
- Publication Type:Journal Article
- MeSH:
Cell Proliferation;
Child;
Humans;
Phosphatidylinositol 3-Kinases;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;
Proto-Oncogene Proteins c-akt;
Signal Transduction;
TOR Serine-Threonine Kinases
- From:
Journal of Experimental Hematology
2016;24(4):1269-1274
- CountryChina
- Language:Chinese
-
Abstract:
The PI3K/Akt/mTOR signaling pathway plays a central role in cell growth, proliferation and survival in physiological conditions. This signal pathway is considered to be an innovative targeted therapy of cancer, and its abnormal activation has been proved to be related to T-cell acute lymphoblastic leukemia (T-ALL) .Despite improved treatment strategies, such as multi-drug combination, high-dose chemotherapy and all kinds of application and popularization of hematopoietic stem cell transplantation, children with drug resistance or relapse T-ALL are still rather worse and its overall outcome and prognosis are much poorer than the more common B-lineage ALL. Therefore, more effective and less cytotoxic treatment targeted strategies for leukemia greatly needed. This review focuses on the relationship between the PI3k/Akt/mTOR pathway and the pediatric T-ALL, so as to reveal the exact molecular mechanism of T-ALL and provide more directions for its treatment.
